# Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout

> **NCT05925166** · NA · COMPLETED · sponsor: **Lihua Duan** · enrollment: 26 (actual)

## Conditions studied

- Acute Gout

## Interventions

- **DRUG:** rhTNFR-Fc
- **DRUG:** methylprednisolone

## Key facts

- **NCT ID:** NCT05925166
- **Lead sponsor:** Lihua Duan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-01-31
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05925166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05925166, "Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05925166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*